All In Biotech

Drug Trial Radar · NCT07830719

Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study of YMI024 to Assess Efficacy in Reducing Inflammatory Markers, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Sep 18, 2026

Primary completion

Aug 15, 2027

Study completion Aug 15, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Sep 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by elevated high-sensitivity C-reactive protein (hsCRP) (≥2 mg/L)

Conditions

  • Coronary Artery Disease

Interventions

  • YMI024Drug

    YMI024 in different doses

  • PlaceboDrug

    matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in log-transformed IL-6Time frame: Baseline and approximately 3 months

Locations

23 sites in 5 countries. Site status is shown where the registry gives one.

  • Eastern Shore Research Institute

    Fairhope, Alabama · Recruiting

  • G and L Research LLC

    Foley, Alabama · Recruiting

  • Biopharma Informatic LLC

    Los Angeles, California · Recruiting

  • AMR Miami

    Coral Gables, Florida · Recruiting

  • Alliance for Multispecialty Research

    Wichita, Kansas · Recruiting

  • Anderson Medical Research

    Ft. Washington, Maryland · Recruiting

  • MD Medical Research

    Oxon Hill, Maryland · Recruiting

  • Pharma Tex Research

    Amarillo, Texas · Recruiting

  • Selma Medical Associates

    Winchester, Virginia · Recruiting

  • Novartis Investigative Site

    Adelaide, South Australia, Australia · Recruiting

  • Novartis Investigative Site

    Frankston, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Melbourne, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Mulgrave, Victoria, Australia · Recruiting

  • Novartis Investigative Site

    Berlin, Germany · Recruiting

  • Novartis Investigative Site

    Mannheim, Germany · Recruiting

  • Novartis Investigative Site

    Pirna, Germany · Recruiting

  • Novartis Investigative Site

    Stuttgart, Baden-Wurttemberg, Germany · Recruiting

  • Novartis Investigative Site

    Kaiserslautern, Rhineland-Palatinate, Germany · Recruiting

  • Novartis Investigative Site

    Kasugai, Aichi-ken, Japan · Recruiting

  • Novartis Investigative Site

    Matsudo, Chiba, Japan · Recruiting

  • Novartis Investigative Site

    Kamakura, Kanagawa, Japan · Recruiting

  • Novartis Investigative Site

    Matsubara, Osaka, Japan · Recruiting

  • Novartis Investigative Site

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.